Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Miami
University of Arkansas
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
National Cancer Institute (NCI)
Columbia University
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Mateon Therapeutics
University of Florida
St. Jude Children's Research Hospital
Karolinska Institutet
Nova Scotia Health Authority
University of Oxford
Jazz Pharmaceuticals
M.D. Anderson Cancer Center
Bayer
Duke University
Northwestern University
G1 Therapeutics, Inc.
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Northwestern University
University Hospitals Cleveland Medical Center
University Hospital, Linkoeping
Aalborg University Hospital
Elevation Oncology
Bayer
Université Catholique de Louvain
Massachusetts Eye and Ear Infirmary
Mayo Clinic
Northwestern University
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Halozyme Therapeutics
EMD Serono
OHSU Knight Cancer Institute
Genentech, Inc.
Merck KGaA, Darmstadt, Germany
Mayo Clinic
Guangzhou First People's Hospital
University of Kentucky
Merck KGaA, Darmstadt, Germany
Arya, Vijaypal, M.D., P.C.
EMD Serono